Recombinant adenoviral vectors are attractive in the context of cancer gene therapy because they are capable of delivering genes to a wide variety of tissues. The utility of adenoviruses is limited by their lack of specificity and by the absence of the receptor(s) for these viruses on many tumor cells. Redirecting adenoviral vectors to tissue-or tumor-specific targets can be achieved by using bispecific conjugates produced by chemical linkage of an anti-adenovirus antibody (Ab) and a ligand or Ab directed toward a specific target. To avoid the limitations of chemical conjugates, molecular conjugates of anti-fiber knob and ligand have been proposed. We present here a novel strategy that allows the production of recombinant bispecific single-chain Abs directed at cell surface molecules. A construct was made that encodes a neutralizing anti-adenovirus fiber single-chain Fv (scFv) Ab (S11) fused to a scFv Ab (425) directed against the epidermal growth factor receptor. The fusion protein markedly enhanced the infection efficiency of adenoviral vectors in epidermal growth factor receptor-expressing cell lines. The bispecific scFv could be purified and concentrated after binding of its 6His tag to a nickel column without significant loss of activity. This approach should permit the production of high quantities of active bispecific scFv for in vivo use. The universal design of the construct allows rapid screening for relevant specific scFv directed at cell surface antigens that can be incorporated into adenoviral targeting strategies. Cancer Gene Therapy (2000) 7, 901-904
A denoviral vectors are widely used in gene therapy because they are highly efficient in gene transfer even in the absence of host cell replication. Targeting of adenovirus (Ad) may allow the administration of fewer adenoviral particles, thus decreasing vector-related toxicity. In addition, it may enhance the infection efficacy of adenoviral vectors on specific cells that express low amount of receptors for these viruses. Hence, targeting the Ads has important implications for in vivo use of these vectors.
Most human adenoviruses bind via the carboxylterminal knob domain of their fiber protein to the recently identified primary cellular receptor Coxsackie/ adenovirus receptor (CAR). 1 After viral attachment, internalization is mediated through clustering of cellular ␣ v integrins by five RGD motifs in the penton base. 2, 3 The targeting of adenoviruses to specific cell types can be accomplished by redirecting the binding to CAR to new antigens using conjugates of anti-fiber knob antibodies (Abs) and ligands. It has been shown that an anti-knob Ab chemically conjugated to a ligand directed against cellular receptors can re-route the entry of adenovirus to the folate receptor, 4 to the fibroblast growth factor receptor, 5 to the epidermal growth factor receptor (EGFR), 6 or to tumor-associated antigens such as epithelial cell adhesion molecule. 7 This type of retargeting of adenoviral vectors was shown to be specific and independent of the natural viral receptor, CAR. 4 -7 The ability to engineer recombinant Abs has facilitated the production of bispecific Abs or fusion proteins. This has resulted in the construction of an "adenobody" consisting of a single-chain Fv (scFv) directed against the adenovirus fiber fused to EGF to target adenovirus to the EGFR. 8 In the present study, we sought to determine whether an analogous approach could be developed by employing a bispecific scFv, directed on one site against the adenovirus fiber and on the other site against a cell surface molecule, the EGFR. The results show that a functional bispecific scFv fusion protein produced in eukaryotic cells could target and enhance the efficacy of adenoviral infection. The approach described herein may be applied more generally with other tumor-or tissue-specific scFv Abs.
RESULTS AND DISCUSSION
To target Ad to the EGFR, a bispecific scFv Ab fusion protein was constructed from the cDNAs of an anti-fiber scFv, S11, 8 and an anti-EGFR scFv, 425. 9 The cDNAs encoding the two scFv Abs were fused in two different orientations, S11-425 and 425-S11, and inserted in a pSecTag plasmid (Invitrogen, Groningen, The Netherlands) (Fig 1a) . The bispecific constructs and the separate scFvs were expressed in COS-7 cells, as prokaryotic expression often leads to nonfunctional bispecific Abs or requires complicated refolding procedures to obtain the desired protein. 10 After transient transfection of the cells, correct protein expression was detected for the scFvs S11 and 425 and for the bispecific scFv fusion proteins 425-S11 and S11-425 by Western blotting (Fig 2a) .
Supernatants containing the bispecific scFvs were tested for binding to recombinant knob by enzymelinked immunosorbent assay (ELISA). (Fig 2b) . Both fusion proteins, S11-425 and 425-S11, bound to recombinant knob, indicating that the fiber recognition was preserved in the fusion protein. Next, we determined whether the bispecific scFvs were capable of binding to EGFR positive cells by flow cytometry. Analysis of A431 cells confirmed the retention of EGFR binding of the scFv fusion proteins (Fig 2c) .
Targeting of an adenovirus encoding LacZ (AdCMVLacZ, 11 ) to EGFR-expressing cell lines was shown with supernatants of COS-7 cells transfected with either bispecific scFv construct (Fig 3) . Using a quantitative assay for LacZ activity (␤-galactosidase (␤-gal) chemiluminescent assay; Boehringer Mannheim, Almere, The Netherlands), we analyzed the targeting of AdCMV- Figure 1 . Construction of bispecific scFv 425-S11. a: A bispecific scFv Ab fusion protein was constructed from an anti-fiber scFv, S11, and an anti-EGFR scFv, 425. The cDNA encoding the scFv 425 was cloned in frame with the 3Ј myc 6His tag of the eukaryotic expression vector pSecTag (Invitrogen). The S11 scFv cDNA was amplified by polymerase chain reaction using Pwo polymerase (Boehringer Mannheim) and ligated directly 3Ј from the scFv 425. , scFv S11 (lane 2), bispecific scFv 425-S11 (lane 3), and bispecific scFv S11-425 (lane 4). After sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% acrylamide) and electroelution onto polyvinylidene difluoride membranes (Bio-Rad, Richmond, Calif), proteins were detected with the anti-myc Ab 9E10 13 and rabbit anti-mouse IgG horseradish peroxidase (HRP)-conjugated Ab (Dako, Glostrup, Denmark). Blots were developed with Lumilight Plus (Boehringer Mannheim). b: Binding to recombinant fiber knob was tested by ELISA. Plates were coated with recombinant fiber knob and incubated with supernatant of transfected COS-7 cells; bound fusion protein was detected with the anti-myc monoclonal Ab 9E10 13 followed by rabbit anti-mouse HRP conjugate (Dako) and o-phenylenediamine substrate. Absorption was measured at 490 nm; E, S11-425; F, 425-S11. c: Binding to EGFR-positive A431 cells was evaluated by flow cytometry (FACScan; Becton Dickinson, Mountain View, Calif) using the anti-myc Ab 9E10 and fluorescein isothiocyanateconjugated rabbit anti-mouse Ab (Dako). 1, control; 2, 425 IgG; 3, bispecific scFv 425-S11; 4, bispecific scFv S11-425.
LacZ in EGFR-positive cell lines with different levels of CAR expression. Two of these cell lines (OVCAR-3 and A549) had high CAR expression 7, 12 and two (A431 and U118) had low CAR expression. 6, 8 All four cell lines exhibited enhanced adenoviral-mediated gene transfer after immunological targeting to the EGFR with the 425-S11 fusion protein. (Table 1) . A similar enhancement was observed with S11-425 when used with similar amounts of fusion protein, based on the knob-binding ELISA (data not shown). The targeting ratio (i.e., the ratio of the LacZ activity of cells infected by AdLacZ with or without bispecific 425-S11 Ab) was at least 10 for three of these cell lines. This suggests that even in cell lines that are CAR-positive, the infection of the adenovirus can be enhanced through targeting via the EGFR pathway. Targeting was not observed with EGFR-negative rodent cell lines (9L or Chinese hamster ovary cells) (data not shown).
The bispecific Ab was purified from the supernatant of transfected COS-7 cells by a nickel-nitrilotriacetate spin column procedure (Qiagen, Hilden, Germany) using the 6His tag present in the construct. The presence of the bispecific Ab in the 250 mM imidazole eluate was confirmed by Western blot analysis using a monoclonal Ab against the myc tag present in the construct (Fig 4a) . Efficient targeting was shown with this eluate, confirming the integrity of the bispecific scFv. This should allow ) were infected with AdCMVLacZ 11 in the presence or absence of the bispecific scFv fusion protein. Virus (25 l) was combined with the supernatant of COS-7 cells, producing the 425-S11 fusion protein (25 l), and incubated for 30 minutes at room temperature. Infection was done for 1 hour in a 24-well plate at a MOI of 1,000 or 10,000 particles/cell according to standard procedures. LacZ activity was quantified after 24 hours by a chemiluminescent assay (␤-gal reporter gene chemiluminescent assay, Boehringer Mannheim). Cells were lysed, and each measurement was done with one-fourth of the lysate. All measurements were done in triplicate. Reading was done with a Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad, Germany) during the 10 seconds immediately after initiation of the light reaction. Values are given in millions of relative light units.
†Ratio between LacZ activities, as measured by chemoluminescence, of cells infected with an MOI of 1000 with and without targeting by bispecific single-chain 425-S11.
‡Ratio between LacZ activities, as measured by chemoluminescence, of cells infected with an MOI of 1,000 and 10,000.
the production of pure fusion protein to be used for in vivo preclinical studies.
In conclusion, the expression of bispecific scFv fusion protein in mammalian cells provides a simple and efficient way to produce an immunological targeting moiety. It allows the construction of bispecific Abs in a single step, without the need for chemical linkage of two components, which results in heterogeneous conjugates.
In addition, bispecific scFvs circumvent the problem of viral clustering, which may occur with bivalent anti-CAR Abs and in vivo trapping in the reticulo-endothelial system through the Fc domain of whole immunoglobulins (Igs). These scFv fusion proteins exhibit tumor specificity and represent an interesting alternative to fusion proteins that include a ligand. 8 The general design of the construct should permit rapid evaluation for relevant specific scFvs that can be instituted into adenoviral targeting approaches. Purification of the fusion protein was done with a nickel-nitrilotriacetate spin column procedure (Qiagen) according to the manufacturer's instructions. After centrifugation at 14,000 rpm for 5 minutes at room temperature, the supernatant from COS-7 cells transfected with the construct encoding bispecific scFv 425-S11 was loaded on the column previously equilibrated with 10 mM imidazole buffer. The column was then washed with buffer solutions with increasing concentrations of imidazole. Western blotting was performed with supernatant and with the different washes and eluates. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% acrylamide) and electroelution onto a polyvinylidene difluoride membrane (Bio-Rad), proteins were detected with the anti-myc Ab 9E10 13 and with rabbit anti-mouse IgG HRP-conjugated Ab. Blots were developed with Lumilight Plus (Boehringer Mannheim). 1, Transfected Cos-7 cell supernatant; 2, 50 mM imidazole stringent wash; 3, 250 mM imidazole elution; 4, 500 mM imidazole elution; M, size markers in kDa.
